Designed jacket that monitors the heart rate and send SMS in case of emergency

30 08 2012

Originally intended to be used by the elderly, students of the Tecnológico de Monterrey, Campus Puebla, they created a vest that monitors vital signs in case of irregularities, enables an SMS message to a call center of medical emergencies.

El chaleco tiene un mecanismo que monitorea los signos vitales y manda un mensaje de alerta cuando se detecta una situación de peligro para la salud.

The jacket has a mechanism that monitors vital signs and sends an alert message when it detects a dangerous situation for health.


The idea came after students of electronic technologies engineer career (ITE) the Tecnológico de Monterrey, Campus Puebla, visit the school of science and technology of the Aalto University in Helsinki, Finland, who works in this device of monitoring and support, as explained by Dr. Francisco Resendiz Rodríguez, Research Professor in the school of information technology and electronics (ETIÉ). 

The Professor entered this jacket may be an alternative for retirement homes and elderly people living alone. The proposal to make its cost manageable, He was to make the production in Puebla. “Here comes at a cost of approximately 10 thousand pesos, If you import of Finland is 400 per cent more expensive”, says Resendiz Rodríguez. 

La Assembly of the World Health Organization warned that in less than three decades one of every four Mexicans will be greater of 60 years and estimated that the population will suffer chronic diseases associated with the cardiovascular system there is no prevention. 

Mientras to the Ministry of health (SSA) reports that currently, There are 10 millions of elderly people in the country of which 20 percent have any limitation in daily activities, so this jacket could save thousands of lives.

Circuits, sensors and transmitters

It is - says- project as “Integrator”, because the application of skills in electronic sensors was needed for its realization, programming and telecommunications 

El vest has a mechanism of three parts: electrical circuits which measure heart rate, sensor body position and alert transmitter. This, to enable it to fulfil the purposes of monitoring and evaluating the normality of vital signs; detect the position of the user and send an alert message when it detects a situation of danger to health. 

La measurement of the heart rate is done through two systems; electronic circuits connected to sensors on the chest area, scheduled with parameters for each person according to the behavior of your body; and Oximeter that work to detect heart rate in the wrist or finger with infrared light. Double checking vital signs makes the alert reliable. 

An accelerometer detects the abrupt movements and the time in which, While the alert is sent through a chip integrated cell that is scheduled to deliver a message to a “Call Center” with the data that shed systems to evaluate if you must send an alert to the user emergency contact. [en línea] Monterrey(MEX):, 30 in August of 2012 [REF. 13 April of 2012] Available on Internet: Informativo/por Tema/Investigacion/chalecosalvacorazones13abr12

CVC and the Hospital de Sant Pau develop a software to determine new parameters of cardiac function

27 08 2012

One of the first clinical applications of this software in the Hospital de Sant Pau in Barcelona is aimed at early detection of cardiotoxicity in patients undergoing chemotherapy.


The computer Vision Center (CVC) of the Autonomous University of Barcelona (UAB), in collaboration with the unit of cardiac image of the cardiology service of the Hospital de Sant Pau, It has developed software that allows, for the first time, in a way easy and useful to the doctor, calculate the torque values myocardial from marked cardiac magnetic resonance imaging analysis (tagging myocardial).

Myocardial torsion is the relationship between form and function of the heart and is an indicator of functionalism global myocardial with a high diagnostic value for the early detection of ventricular dysfunction.

The software has been done in the framework of the Project myocarditis. Led by the Dra. Debora Gil interactive and increased modeling group (IAM) the CVC and the Dr. Francesc races of the Hospital de Sant Pau, the ultimate goal of this project is to model and assess the electro-mechanical functioning of the heart, in order to deepen the knowledge of heart mechanics in the healthy heart and the disease. 

 software has been integrated into the free access platform OsiriX. A key feature is that the interface has been created by and for clinical, This ensures the use in situ by doctors within the own laboratory for image of hospitals.

A prototype has been operating in the heart image of the Hospital de Sant Pau unit since September of 2011. 

Recently, the Hospital has adopted a protocol to use this software on a prospective basis for patients receiving chemotherapy treatment potentially cardiotoxica in order to detect early stage possible the occurrence of ventricular myocardial dysfunction. The software implemented at the Hospital Sant Pau will facilitate the work of doctors, by providing new ventricular function parameters that are useful for monitoring and early detection of cardiotoxicity in patients undergoing chemotherapy. [en línea] Barcelona(ESP): ua@UAB.es27 in August of 2012 [REF. 19 April of 2012] Available on Internet: = 1334730416560

A new kit makes the diagnosis of colon cancer, and rectum

23 08 2012

The University of Salamanca participates in the development of a new method of early cancer of the colon and rectum diagnosis. The increase in the prevalence of this type of tumours requires before and better these tumors or its recurrence to be able to reduce mortality. The objective is to develop a kit for any hospital, quickly and automatically, the test and get the results.


Células cancerígenas de cólon Imagen: Euthman.

Image colon cancer cells: Euthman.

The Colodetect project aims to advance the diagnosis of colon cancer and straight through the study of molecular markers that determine the existence of the tumor in a simple blood sample. The increase in the prevalence of this type of tumours requires before and better these tumors or its recurrence to be able to reduce mortality.

The University of Salamanca takes part in research, led by the Madrid company Proalt, which aims to develop a kit for any hospital, quickly and automatically, the test and get the results.

“Colorectal cancer is a very serious problem because the number of patients is increasing in developed countries. A diagnosis early would treat them early”, stated in declarations to DiCYT Francisco Javier García Criado, Dean of the Faculty of medicine and head of the study by the University of Salamanca.

In this quest for a diagnosis early, Some proteins found in blood samples can be converted in tumor markers. “Their alteration tells us that there may be a neoplastic process or operated cancer relapse and returns to neoplastic activity. The problem is that sometimes those markers are not all the specific thing that we would like to, other diseases can cause false positive or, What is worse, We have false negative results”, indicates.

Why, the objective is to identify new proteins whose presence in the blood indicate unequivocally the diagnosis and, based on this knowledge, develop a test in a format allowing you to conduct a test in a hospital in the quickest and easiest way.

“What is interesting is that these proteins appear early en Cáncer de colon and rectum, so when your number it amounts in the blood means that we we have this type of tumor”, says García Criado.

Cheap and early diagnosis

The current status of the study, already advanced and positive preliminary results, “It makes us be optimistic before the validity of the final kit”, ensures the expert. “We think that the diagnosis can be obtained is highly reliable and will be translated in a cheap and early diagnosis”, Adds.

Scientists have already identified some very specific proteins and are working with them. “Possibly instead of using one single kit have to combine several for the specificity that we”, says researcher. In any case, This would prevent the complex and very expensive current evidence.

Prior to this research, had already identified specific proteins in patients, but it is also necessary to compare this information with people who suffer from other diseases and healthy individuals, to overcome the contradictory results of some markers.

The research that will lead to the development of the kit expected to have samples of each 2.000 patients, It will serve to verify the presence in the blood of some proteins is directly linked to cancer of the colon and rectum.

The project is not intended to become an extension of the basic knowledge, but to arrive at the hospital as soon as possible, Why participating companies that undertake to take the following steps to bring this research to clinical practice. In addition to Proalt, the Biomedal company is also involved, (e) public institutions such as the National Cancer Centre (CNIO). [en línea] Madrid(ESP):, 23 in August of 2012 [REF. 16 in July of 2012] Available on Internet:

They question the value of a marker of myocardial in one third of patients

20 08 2012

The use of Troponin in diagnosis of acute myocardial infarction remains undisputed, Although its measurement could overestimate the size of infarction in patients with left ventricular hypertrophy. The finding will change future studies assessment of cardioprotective interventions and new drugs.


En la foto se observa un infarto en la pared anterior del corazón. Imagen: Wikipedia.

The photo shows a heart attack in the anterior wall of the heart. Image: Wikipedia.

A study of the national centre of cardiovascular research (CNIC) and the Hospital Clínico San Carlos of Madrid casts doubt on the value of a commonly used marker to assess myocardial infarction, protein troponin, in about one-third of the acute myocardial infarction (IAM) with ST-segment elevation.

According to Rodrigo Fernandez-jimenez, first signer of the study, This type of heart attacks are "of worse prognosis and require urgent action", "ideally by primary angioplasty".

In particular, as points out the work published in the Journal of the American College of Cardiology (JACC), troponin would not be a correct indicator of the size of infarction in individuals who have some degree of left ventricular hypertrophy (HVI), "one-third of the patients who suffer from this type of IAM".


Left ventricular hypertrophy is "very common", because it is highly associated with high blood pressure, "very common in this type of sick", explains Valentin Fuster, Director general of the IASB and author of the study.

The problem detected by the researchers of the CNIC It is that the troponin significantly overestimated the size of the stroke in these patients and according to Fuster "can give the impression of the infarction is more bulky than it is in reality".

The researchers assessed to 937 patients who entered between 2004 and 2009 in the service of cardiology at the Hospital Clínico San Carlos with the diagnosis of acute myocardial infarction with ST-segment elevation (STEMI, for its acronym in English).

As laid down in the Protocol, determined by serial analysis of Troponin and creatine kinase total maximum values. "It is a common practice in the day to day", "since you been correlated way close with the prognosis and the size of the heart", points Fernandez-jimenez.

However, and form pioneer, the authors analysed biomarkers separately and according to the presence or not of hypertrophy, Noting that, While the creatine kinase total remained stable in patients who had a heart attack of certain size, troponin levels vary significantly if the sick had left ventricular hypertrophy.

The figures of variation depended on the level of hypertrophy. Like this, patients with mild HVI had a level of Troponin I – protein that is part of the troponin complex – a 13,7% higher than individuals who did not show hypertrophy. The difference increased to the 17,8% in patients with moderate to severe HVI.

Practical implications

First of all, Although "the pharmacological treatment applied to these patients is similar in all of them", follow more closely to those with larger strokes, "because they may require more specific treatments to improve their quality of life or treat malignant arrhythmias".

An incorrect assessment of the size of myocardial troponin level might involve excessive surveillance and diagnostic tests in a not-so-serious heart attack, as well as an incorrect information to the patient and the family.

In the second place, Fernandez-jimenez says, the finding will have a great impact on the future assessment of cardioprotective interventions and drugs, Since "numerous works that have assessed the use of these treatments have been used as main evaluation parameter measured by troponin infarction size".

Have been taken into account the important findings of the work "the results of these studies may have changed", so, the researcher predicts, "there will be present in the design of future work". [en línea] Madrid(ESP):, 20 in August of 2012 [REF. 24 in July of 2012] Available on Internet:

Anticoagulants are safe in patients treated with warfarin after a stroke

16 08 2012

The medication that dissolves clots, called Tissue plasminogen activator (tPA, for its acronym in English), It is safe to use in patients with acute stroke, you are already in treatment with warfarin, According to researchers at the Duke Clinical Research Institute (DCRI).   


This study helps dispel concerns about tPA, as it was thought that it was too dangerous for use in patients already treated with anticoagulation, and that could cause life-threatening intracranial hemorrhages. The new research has been published in the magazine ‘JAMA‘.

“To date, There were no randomised trials or large cohort studies to guide us”, explains Dr Ying Xian, Professor of medicine at Duke, and lead author of the study. According to Xian, “our new study at national level did not find a statistically significant increased risk, which supports the use of intravenous tPA in patients treated with warfarin, If your INR is equal or less to 1.7″.

The INR (International Normalized Ratio), It measures the speed at which blood coagulates in patients taking blood thinning drugs, like warfarin.


The Duke researchers also noted that almost half of the patients treated with warfarin, that there may be a benefit from treatment with tPA, they did not receive this treatment. According to Eric Peterson, main author of the article “a substantial proportion of patients taking warfarin, did not receive tPA After his stroke”.

Warfarin is an anticoagulant which reduces the rate of stroke in patients with atrial fibrillation - irregular beats of the heart. If treatment with warfarin fails, and the patient suffers a stroke, the tPA is the only effective treatment. However, It also carries an increased risk of symptomatic intracranial hemorrhage. The guidelines of the American Heart Association says that the tPA, in patients treated with warfarin, It can be used if the INR is less than or equal to 1,7, but few studies support these guidelines.


The new observational study of Duke included to 23.437 patients with Ictus, of 1.203 hospitals, analyzing the use of tPA, en pacientes en tratamienfo with warfarin, and in patients not taking this anticoagulant. While warfarin-treated patients had slightly higher rates of intracranial hemorrhage than the patients not treated with warfarin (5,7% vs 4,6%), these patients also had an older. After making adjustments for age, the severity of the stroke, and other factors, the risk of intracranial hemorrhage was similar.

“This study provides support for the current treatment guidelines”, says Xian, (e) indicates that a portion of the population is being sub-tratada. On the other hand, According to the researcher, “more studies are needed to analyze the use of tPA in patients with one INR greater of 1.7, as well as those who are taking one of the new alternative to warfarin anticoagulants (dabigatran and rivaroxiban)”.


Diariosalud.NET [en línea] Montevideo(URU): diariosalud.NET, 16 in August of 2012 [REF. 30 in June of 2012] Available on Internet: http://diariosalud.NET/index.php?option = com_content&task = view&ID = 24713&Itemid = 413

A spray that covers the skin and Heals wounds

13 08 2012

Scientists created a spray solution composed of cells of the skin that is placed over wounds and can heal them.

El espray está hecho de células de la piel y proteínas anticoagulantes.

The spray is made of skin cells and anticoagulant proteins.

The treatment has been tested with 228 patients suffering from leg ulcers, the most common form of ulcer, It is an open and painful injury that can last for months.

The study carried out, published in the magazine The Lancet, It showed that ulcers treated with spray managed to heal faster and better than the wounds healed with conventional treatment, the compression bandage.

Despite the fact that the spray has a high cost, experts say that in the long term could be treatment cost-effective.

Venous leg ulcers are very difficult to treat.

The compression bandage achieved only cure 70% of these injuries after six months of treatment.

Other options include carrying out grafts on the wound with skin donated.

Spray, made from donated skin cells and anticoagulant proteins, creates a layer covering the ulcer.

In the study, carried out by researchers from Canada and United States, patients who received a dose of spray each 14 days showed the biggest improvement.

According to scientists, the size of the wound “began to quickly reduce” as soon as he began treatment.

Among patients who received the spray, 70% they were cured after three months of treatment.

Among those who received other therapies only 46% healed.

Difficult to treat

The spray was developed by the American company Healthpoint Biotherapeutics, that also funded the study.

One of the scientists involved, Dr. Herbert Slade, says that “the treatment that we tested in this study has the potential to greatly improve the recovery time and the general recovery of leg ulcers, without the need to carry out a skin graft”.

“This not only means that the patient will not develop a new wound where the graft was removed, but also that the spray solution may be available when required”.

“Skin grafts need to be prepared with some time before, which exposes the patient to more discomfort and risk of infection” Adds the researcher.

The study analyzed mainly the safety of treatment and the most appropriate dose, and now future studies will decide if it is a practical treatment for leg ulcers.

These wounds are mainly caused by high blood pressure in the veins of the legs which damage the skin by causing the development of the open wound.

As explains Irene Anderson, expert at the University of Hertfordshire leg ulcers, England, “a bandage or another application can have a positive effect on the wound for a period of time”.

“But eventually if the underlying disorder is handled properly will return leg to develop the lesion”.

“We know that leg ulcers are becoming increasingly difficult to treat and when we use available treatments need to have clear evidence that will have a beneficial effect to ensure that they are cost effective and that the patient does not have false expectations for a cure”. [en línea] London(UK): de agosto de 2012 [REF. 04 in August of 2012] Available on Internet:

Dr.Smartphone: Pocket Telefono-medico [LifeWatch]

9 08 2012

They released a new device of the LifeWatch signature in Switzerland, It manufactures phones built for medical purposes. It is capable of monitoring various physiological variables and ensure that it can be useful even to save lives at a distance.

 Many medical lovers of new technologies were anticipating it, but nobody imagined that what looked like futurology become soon a reachable product to a minimum click: simply enter the firm's web site to check (and even buy it, If any desired). Any person with desire or need to permanently control some variables medical body can acquire the new LifeWatch V and take to the doctor with you, in the pocket of the pants or portfolio.

It is indisputable: smart phones and tablets will have much to do with our health in the coming years. Applications that disclose knowledge, help to follow treatments and training and to monitor checks and physiological variables, joined the smartphone with high fidelity sensors that allow us to measure parameters that previously required enormous apparatus, expensive and of a medical institution.

The new device is called LifeWatch and its creators claim that it can be useful even to save lives at a distance. It is a phone, of course, but it is much more: is an electrocardiograph, a blood sugar meter, a thermometer and a device capable of Objectifying the saturation of oxygen in blood, the heart rate, the level of stress and even the percentage of body fat.

Although there are already several external sensors for smartphones capable of measuring our heart rate in the market, temperature and many more on our body data, the novelty of V is LifeWatch who has managed to embed all these sensors in your mobile phone.

Thanks to several sensors on the periphery and back of the phone, LifeWatch V is capable of measuring your temperature, your body fat, your glucose, your heart rate, your level of stress, your temperature and your blood oxygen level. In addition, in only 25 seconds can also make you a relatively detailed and accurate ECG.

All this in an Android smartphone that also has several applications that measure and record data with sensors, the doctor sends by mail, Remember medications you should take and helps keep track of your diet, among other things.

In some years, When costs fall (by now costs about thousand euros) and technology adoption increases, It is likely that many doctors use these devices to monitor their patients. Of them chronic patients who need to monitor their health with relative frequency will also benefit, especially diabetics.

Taringa.NET [en línea] Buenos Aires (ARG): taringa.NET, 09 in August of 2012 [REF. 15 in July of 2012] Available on Internet: http://www.taringa.NET/posts/Salud-Bienestar/15212289/Dr_Smartphone_-Telefono-medico-de-bolsillo_-LifeWatch_.html

DR BLANCH: Knowledge and vision

6 08 2012

Lluís Blanch MD, PhD.

Senior intensive care medicine

Director research and innovation,

Corporation University Health Parc Taulí

Cyber respiratory diseases

Universitat Autònoma de Barcelona


Often we get news related to scientific discoveries that will bring improvements in the treatment and care of patients in the short or long term. The primary objective of the research is always to improve the diagnosis and treatment of disease, studying their origin, the reason for its development in people, its impact on the body and the possible prevention, way of improvement, or healing. This is the main return society obtained from research.


The duty of every scientist is to disseminate the knowledge that the research gives it to contribute to the collective progress in the treatment of disease, but is fair and - increasingly- necessary the investigator also adopts a new corporate vision and apply his achievements since, do not, sectors that have not participated in the personal effort or institution which supports him, they will get the possible economic performance. For all these reasons, It is necessary that when the result of a research project is likely to be of interest to the market, the investigator or the institution protects intellectual property, as well as the future exploitation rights and, protected once, proceed to the revelation of the scientific progress in Congress, publications, etc … A single datum can perfectly illustrate this idea: Despite being a country that is excellently positioned in terms of scientific publications, Spain recorded during the 2011 nearly half of patents registered only by the IBM company, they were 6180.


Health centers and hospitals are territories of excellence for research and innovation. In an unstable environment as the current, We can and we must seek economic performance in what until recently was exclusively social performance, Since our focus is on ensuring a return of resources that enable forward scientifically. Our country generates much knowledge since it has excellent and hard-working professionals,If they adopt an appropriate culture of entrepreneurship, It would only take determined and convinced the management involvement and support. It's vision of the future.

Inhaled nitric oxide shown safe as potential antimicrobial treatment: UBC-VCH research

2 08 2012

Results from a clinical study by a UBC-Vancouver Coastal Health research team have increased hope for a new, effective and inexpensive anti-microbial treatment using inhalable nitric oxide.

Nitric oxide is produced naturally by the body’s immune system and is a potent anti-microbial agent against bacteria, viruses, fungi, and parasites, but the safety of nitric oxide given to humans at microbe killing concentrations has not been studied until now.

In the new study, published in this month’s edition of the Journal of Cystic Fibrosis, healthy adult volunteers show no adverse effects associated with therapeutic antimicrobial concentrations of nitric oxide. The study was conducted at UBC Hospital, where healthy volunteers were recruited and inhaled nitric oxide gas was administrated over a period of one week.

“In retrospect, it’s not surprising to find that a molecule naturally produced in our own body to fight invading pathogens is useful as an antimicrobial drug,” says lead author Prof. Chris Miller, assistant professor in UBC’s Division of Respiratory Medicine and a member of the Immunity and Infection Research Centre at the Vancouver Coastal Health Research Institute. “This study confirms the safety aspect of an efficacious mode of delivery.”

This Phase I safety study was funded by the Lotte & John Hecht Memorial Foundation, and leads the way to efficacy studies targeting the spread of resistant pulmonary infections – focusing first on Cystic Fibrosis and Tuberculosis,  a deadly pulmonary infection  that kill millions of people every year. The study results were licensed by the UBC Industry Liaison Office to AIT, an Israeli company.

The UBC Faculty of Medicine provides innovative programs in the health and life sciences, teaching students at the undergraduate, graduate and postgraduate levels. Its faculty members received $295 million in research funds, 54 percent of UBC’s total research revenues, in 2010-11. For more information, visit

Vancouver Coastal Health Research Institute (VCHRI) is the research body of Vancouver Coastal Health Authority, which includes BC’s largest academic and teaching health sciences centres: VGH, UBC Hospital, and GF Strong Rehabilitation Centre. In academic partnership with the University of British Columbia, VCHRI brings innovation and discovery to patient care, advancing healthier lives in healthy communities across British Columbia, Canada, and beyond. [en línea] Vancouver (CAN):, 02 in August of 2012 [REF. 03 in July of 2012] Available on Internet: